EMA Committee Makes Decisions on Opioids, Follow-on Biologics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Committee Makes Decisions on Opioids, Follow-on Biologics


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued on Nov. 19, 2010, a summary of its latest meeting. Two key outcomes of the meeting include the agency’s procedure on modified-release oral opioids and its procedures for reviewing certain biosimilars.

With regard to opioid-based drugs, the committee finalized a re-examination procedure on modified-release oral opioid products for the management of pain at level III of the World Health Organization’s pain-management scale (i.e., the use of strong painkillers when other drugs have failed to control pain). Confirming its initial opinion [see background], CHMP recommended the suspension of formulations using polymethacrylate-triethylcitrate controlled-release systems. The reason, according to the summary, has to due with the products' interactions with alcohol. CHMP also recommended harmonizing current warnings on these products regarding their use in conjunction with alcohol.

On the topic of follow-on biologics, or biosimilars, CHMP adopted a draft guideline, Similar Biological Medicinal Products Containing Monoclonal Antibodies. This guideline describes nonclinical and clinical testing requirements for drugs that contain monoclonal antibodies that also claim to be similar to a drug already on the market. The guideline, to be published on the agency’s website, will be open to public comment for the next five months.

Finally, the committee adopted decisions on various applications from industry, such as those proposing extending treatment options for certain drugs already on the market in the European Union, and for restricting the use of modafinil-containing medicines. The full CHMP summary can be found on the EMA website.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here